NEWS

WASHINGTON, D.C. (Dec. 29, 2025) – We Work For Health commends the Trump administration for recognizing the substantial role corporate insurers and their integrated subsidiaries play in driving up costs and restricting access to care for American families. The administration's announcement of their intent to bring healthcare insurance executives to the table and examine the full scope of insurance industry practices represents the most necessary and critical step toward meani

In April, a bipartisan committee warned Congress that America’s global biosector leadership was potentially on borrowed time, advising that if not for urgent regulatory corrections, China will overtake the U.S. within three years. That same committee has issued an update. The clock is ticking even faster than feared. “Since the publication of that assessment , the trajectory the Commission identified has continued – and in several respects intensified,” said the National Secu

A historic 2025 is coming to a close for America’s biopharmaceutical sector. From coast to coast, dozens of companies announced or broke ground on next-generation research facilities, expanded their stateside manufacturing capacity, and laid the foundation for accelerating medical breakthroughs. According to We Work For Health’s U.S. Biopharma Investment Watch , the industry committed more than $492 billion  in new domestic investment this year. The unprecedented capital depl

WASHINGTON, D.C. (Dec. 19, 2025) We Work For Health released the following statement today in response to the Centers for Medicare & Medicaid Services announcing the Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) models:   “Applying the most favored nation (MFN) pricing models to Medicare Parts B and D – including sweeping Medicare demonstrations that would mandate price controls across broad categories of Part

By: Debbie Hart, CEO, BioNJ and Dan Leonard, Executive Director, We Work For Health Will the epicenter of global medical innovation be in New Jersey or Shanghai? That is a critical question before U.S. policymakers right now, and the stakes arguably couldn’t be higher. How the country fends off China’s rising biopharma sector affects everything from our health and national security to local, state and national economies. Today, the U.S. leads the world in biopharmaceutical in

Over the past decade, China has executed a sustained, long-range strategy to build a globally competitive biopharmaceutical sector. Through coordinated investment and policy, the country has moved from “me-too” products to cutting-edge therapies, while elevating regulatory and manufacturing standards to global norms. And it’s working.   On Dec. 11, We Work For Health convened a full room of stakeholders for a critical discussion on China’s accelerating biopharmaceutical ambit

We Work for Health's Executive Director Dan Leonard recently sat down with Dr. Gary Puckrein, President and CEO of the National Minority Quality Forum (NMQF), to discuss his organization's work to ensure fair access to life-saving research and emerging treatments as well as what needs to be done to preserve America's innovation leadership.   The discussion highlighted the public health and economic imperatives of maintaining U.S. competitiveness in biopharmaceutical research

November 26, 2025   (Washington, DC) We Work For Health Executive Director Dan Leonard issued the following statement in response to the administration’s announcement on the Maximum Fair Prices (MFP) for IPAY 2027 selected drugs:   “We Work For Health has been sounding the alarm about the dangers of government price controls since the passage of the Inflation Reduction Act (IRA). This latest announcement from the Administration is yet another troubling consequence of that pol